MTOR and depressive symptom measurement: Li et al. reported that the mTOR pathway activated by ketamine increases the levels of synaptic signaling proteins (synapsin I, PSD95, and GluR1) and increases the number and function of new synapses in the prefrontal cortex of rat models of depression [33].